BioCentury
ARTICLE | Clinical News

ARG201: Phase II data

July 7, 2008 7:00 AM UTC

In a double-blind, U.S. Phase II trial in 168 patients, oral ARG201 missed the primary endpoint of a significant improvement in MRSS vs. placebo. In a prospectively defined subgroup of late phase pati...